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The importance of chronic inflammation as a risk 
factor for major cancers is well documented [1], and the 
inflammatory state is known to involve contributions 
of both adaptive and innate immune components.  In 
a recent publication [2] we describe an experimental 
animal model in which infection, inflammation and 
cancer are mechanistically linked, and provide evidence 
that chemical mediators of the innate immune system 
and bacterial toxins both play key roles in driving colon 
carcinogenesis.  In this model, epithelial injury caused 
by Helicobacter hepaticus infection enhances access of 
bacterially-associated products to pattern-recognition 
receptors located on surfaces of macrophages and dendritic 
cells.  Receptor ligation leads to activation of transcription 
factors, including NF-kappa B, that regulate production 
of chemo-attractants for macrophages and neutrophils, 
recruitment of which is a hallmark of inflammation.  These 
acute inflammatory events are re-enforced by expression 
of powerful inflammatory mediators such as TNF-α and 
IL-2, which amplify acute inflammatory gene expression 
and enhance cell survival.   If not properly extinguished, 
the innate inflammatory response is maintained and 
further amplified by activation of cell-mediated adaptive 
immunity. 
There is now strong evidence that biomolecular 
damage found in inflamed tissues is caused by a battery 
of highly reactive oxygen and nitrogen species capable 
of damaging all classes of biomolecules.  Reactive 
species are generated mainly by activated macrophages 
and neutrophils, but can also be produced at functionally 
significant levels endogenously within epithelial cells 
themselves [3, 4]. In an earlier investigation [5], we 
identified the critical importance of NO and neutrophils 
in the carcinogenic process, and in our recent study [2] 
we demonstrated that neutrophils contribute to DNA 
damage through myeloperoxidase-driven formation 
of hypochlorous acid and the subsequent formation of 
5-chlorodeoxycytosine.  These chemicals and reaction 
products derived from them cause injury, death and 
mutation to cells in their immediate environment, the 
ultimate result being intensification of damage inflicted 
by the inflammatory process. 
What we have also learned from recent studies is 
that cell death and genotoxicity in this environment are 
not induced solely by chemicals arising from immune cells 
or epithelial cells, but that these effects are augmented by 
bacterial toxins (e.g., cytolethal distending toxin in H. 
hepaticus) that cause DNA strand breaks, inhibit ATM-
dependent response pathways, and suppress repair of 
DNA adducts [6, 7].  Concurrence of the two mechanisms 
of DNA damage and compensatory increases in cell 
replication creates a perfect storm of conditions enhancing 
the probability of neoplastic transformation. 
Inflammation associated with infections can occur 
over protracted periods of time. DNA damage induced 
as a result of inflammation is potently mutagenic, and 
infection followed by inflammation is a biologically 
plausible scenario that could explain the abundant 
mutations observed in some human tumors.  Inflammatory 
bowel disease (IBD), which is known to be associated 
with increased cancer risk, is particularly relevant to our 
continuing efforts to elucidate mechanisms underlying 
these interactions.  IBD results from intermittent and 
severe activation of the mucosal immune system in the 
gastrointestinal tract to promote chronic inflammation. 
Infiltration of gut tissue by lymphocytes, neutrophils, 
and macrophages results in prolonged exposure to pro-
inflammatory cytokines and to highly reactive chemical 
species that induce oxidation, nitration and chlorination 
of DNA, RNA and proteins. Secondary effects also result 
from oxidation of unsaturated lipids, creating a cascade of 
highly reactive unsaturated carbonyls, which also damage 
DNA, RNA, and proteins.  Chronic exposure to products 
of inflammation can thus result in chemical damage to 
all classes of cellular macromolecules, altered protein 
expression, and dysregulated cell proliferation. 
Current theories cite the intestinal microbiome 
in IBC as a central driver of both inflammation and 
subsequent development of dysplasia in genetically-
predisposed individuals, acting similarly in experimental 
models involving mice with immune dysregulation. 
These processes appear likely to be associated with the 
pathogenesis of cancer development.  Interestingly, 
other investigators recently identified a genetic locus, 
Hiccs, part of a 1.71-Mb interval on chromosome 3, as 
a major susceptibility locus for H. hepaticus-induced 
colitis and colon cancer in H. hepaticus-infected 129 Rag-
/- mice also treated with azoxymethane [8].  This locus 
controls induction of the innate inflammatory response 
by regulating cytokine production and granulocyte 
recruitment by Thy1+ innate lymphoid cells. Analogous 
pathways may be operable in IBD and associated 
colorectal cancers in humans. 
While alterations of the intestinal microbiome have 
been described in IBD patients, with suggestions that 
particular species may be associated with ileal Crohn’s 
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disease, no individual bacterial species or groups have 
been consistently associated with either colonic Crohn’s 
disease or ulcerative colitis.  Likewise, the role that 
microbial biomolecular activity may play in these diseases 
remains unknown.  Metabolomic analysis of fecal water 
from patients with these diseases has identified microbial 
population shifts suggesting that functional capacity 
may be more critical than microbial membership [9]. 
While chronic inflammation is widely thought to be a 
critical factor, biomolecular pathways implicated in the 
development of IBD-associated colon cancer remain 
incompletely characterized.
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